Evidence map›Paper›PMID 29658571›Full record

ArticleInternational journal of oncology2018

Upregulation of HOXA1 promotes tumorigenesis and development of non‑small cell lung cancer: A comprehensive investigation based on reverse transcription-quantitative polymerase chain reaction and bioinformatics analysis.

Yu Zhang, Xiao-Jiao Li, Rong-Quan He, Xiao Wang, Tong-Tong Zhang, Yuan Qin, Rui Zhang, Yun Deng, Han-Lin Wang, Dian-Zhong Luo and 1 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.7field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Functional significance of miR-218 in lung cancer.Journal of cancer metastasis and treatment · 2026
    Article
  3. The role of HOXA1 in cancer and targeted therapy.Medical oncology (Northwood, London, England) · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yu ZhangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Xiao-Jiao LiDepartment of Positron Emission Tomography-Computed Tomography, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Rong-Quan HeDepartment of Medical Oncology,, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Xiao WangDepartment of Orthopedics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250012, P.R. China.
Tong-Tong ZhangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Yuan QinDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Rui ZhangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Yun DengDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Han-Lin WangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Dian-Zhong LuoDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Gang ChenDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Guangxi Medical University · CNFirst Affiliated Hospital of GuangXi Medical University · CNShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Homeobox A1 (HOXA1) serves an oncogenic role in multiple cancer types. However, the role of HOXA1 in non‑small cell lung cancer (NSCLC) remains unclear. In the present study, use of reverse transcription-quantitative polymerase chain reaction and the databases of The Cancer Genome Atlas (TCGA), Oncomine, Gene Expression Profiling Interactive Analysis and the Multi Experiment Matrix were combined to assess the expression of HOXA1 and its co-expressed genes in NSCLC. Bioinformatic analyses, such as Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and network and protein-protein interaction analyses, were used to investigate the underlying molecular mechanism effected by the co-expressed genes. Additionally, the potential miRNAs targeting HOXA1 were investigated. The results showed that HOXA1 was upregulated in NSCLC. The area under the curve of HOXA1 indicated a moderate diagnostic value of the HOXA1 level in NSCLC. According to GO and KEGG analyses, the co-expressed genes may be involved in 'dGTP metabolic processes', 'network-forming collagen trimers', 'centromeric DNA binding' and 'the p53 signaling pathway'. Three miRNAs (miR‑181b‑5p, miR‑28‑5p and miR‑181d‑5p) targeting HOXA1 were each predicted by 10 algorithms; miR‑181b and miR‑181d levels were downregulated in LUSC tissues compared with those in normal lung tissues based on data from the TCGA database, and inverse correlations were found between HOXA1 and miR‑181b (r=-0.205, P<0.001) and miR‑181d (r=-0.106, P=0.020). We speculate that HOXA1 may be the direct target of miR‑181b‑5p or miR‑181d‑5p in LUSC, and HOXA1 may serve a significant role in NSCLC by regulating various pathways, particularly the p53 signaling pathway. However, the detailed mechanism should be verified by functional experiments.

Indexed as

CarcinogenesisCarcinoma, Non-Small-Cell LungComputational BiologyDatabases, GeneticGene Expression Regulation, NeoplasticGene OntologyHomeobox A1 ProteinHomeodomain ProteinsHumansMicroRNAsSignal TransductionTranscription FactorsTumor Suppressor Protein p53Homeobox A1 ProteinHomeodomain ProteinsMicroRNAsTranscription FactorsTumor Suppressor Protein p53

Identifiers

PMID29658571
PMCPMC5958640
OpenAlexW2802107227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.